Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)
Status:
Unknown status
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Lipoprotein (Lp)(a) has been associated with increased risk of cardiovascular disease. Niacin
has been shown to lower Lp(a) in patients with normal or moderately elevated levels. However,
there are few studies assessing the effectiveness of niacin in Lp(a) levels above 30 mg/dl.
In addition, most studies investigating the effectiveness of niacin have only included small
numbers of patients. Also, Lp(a) was only assessed as a secondary endpoint. The aim of the
present study was, therefore, to evaluate whether Niacin is effective compared to placebo in
the reduction of an elevated Lp(a).